Insilico Medicine Signs $2.75B AI Drug Discovery Deal With Eli Lilly

3 Mins Read

Pharmaceutical giant Eli Lilly has struck one of the largest AI drug discovery deals in history, signing a collaboration with Hong Kong-based Insilico Medicine worth up to $2.75 billion, according to an announcement made on March 29, 2026. The deal signals a decisive shift in how the world’s biggest drug companies are approaching research and development — with artificial intelligence moving from a supporting tool to the core engine of discovery.

The agreement gives Lilly exclusive global access to Insilico’s AI platform across multiple therapeutic areas, while also launching new joint research programs targeting diseases with the highest unmet medical need.

What Is Insilico Medicine?

Insilico Medicine is a Hong Kong-based, clinical-stage biotech company built entirely around generative AI for drug discovery.

Insilico’s Pharma.AI platform uses generative AI and large language models to speed up drug discovery, scientific research, and sustainability. The company describes it as an end-to-end tool capable of discovering and designing a small-molecule or biologic drug alongside the biomarker for patient selection.

The company’s pipeline spans:

  • Generative molecule design from scratch
  • Novel disease target identification
  • Biomarker discovery for patient selection
  • Preclinical candidate development across multiple therapeutic areas

Insilico has developed at least 28 drugs using generative AI tools, with nearly half already at a clinical stage.

Insilico completed its IPO on the Hong Kong Stock Exchange on December 30, 2025, raising around $290 million — one of the largest biotech IPOs in Hong Kong in 2025.

What the Deal Actually Covers

The agreement is structured in two parts — a licensing deal and an active research collaboration.

Under the agreement, Lilly was granted an exclusive global license to use Insilico’s AI for the drug development, manufacturing, and commercialization of potential therapeutics. The partners will also collaborate on multiple research and development programs by combining Insilico’s Pharma.AI platforms with Lilly’s disease knowledge and development capabilities, with Lilly selecting the focus areas.

On the financial side:

  • $115 million paid to Insilico upfront
  • Up to $2.75 billion in development, regulatory, and commercial milestones
  • Tiered royalties on all future product sales

Lilly will get an exclusive worldwide license to develop, manufacture, and commercialize oral drugs across multiple therapeutic areas. The companies did not disclose specific disease targets.

Why Eli Lilly Is Making This Bet

This is not Lilly’s first move into AI-driven drug discovery. There are three clear reasons behind the investment.

1. Compressing the Drug Discovery Timeline

Traditional drug discovery takes over a decade and billions of dollars. Lilly gets to drastically compress its discovery timelines, replacing traditional trial-and-error with generative precision. In the hyper-competitive race to cure complex diseases, speed is the ultimate currency.

2. Building AI as a Scientific Collaborator

In October 2025, Lilly partnered with NVIDIA to build what it called the most powerful supercomputer in pharma, designed to synthesize findings from millions of experiments to optimize drug discovery and shorten development cycles. Lilly’s chief AI officer said at the time: “Lilly is shifting from using AI as a tool to embracing it as a scientific collaborator.”

3. Staying Ahead in a Crowded AI Race

Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb, and AstraZeneca are all ramping up the use of AI in drug discovery.For Lilly, securing exclusive access to Insilico’s platform locks out competitors from one of the most advanced generative AI pipelines in the industry.

The Bigger Trend: AI Is Reshaping Drug Discovery

This deal is part of a much larger wave transforming the pharmaceutical industry.

The companies first joined forces in 2023 with an AI software licensing agreement. They deepened their partnership with a $100 million deal in November 2025, and have now expanded again to this $2.75 billion collaboration.

Insilico itself has been rapidly dealmaking across multiple fronts — including a potential $888 million development and discovery pact with Servier, a $120 million deal with Qilu to develop cardiometabolic disease assets, and a $66 million agreement to split rights to its Parkinson’s asset with Hengrui Therapeutics.

The pattern is clear: major pharma companies are racing to secure exclusive AI discovery capabilities before competitors do.

Challenges Ahead

Despite the momentum, AI drug discovery still faces significant hurdles:

  • Clinical validation — AI-designed molecules must still prove safe and effective in human trials
  • Regulatory uncertainty — drug agencies are still developing frameworks for AI-generated therapeutics
  • Data quality risks — AI models are only as good as the biological data they are trained on
  • Translation gap — moving from preclinical AI discovery to approved drugs remains slow and expensive
  • Geopolitical complexity — Insilico develops its AI in Canada and the Middle East but conducts early preclinical work in China, creating potential regulatory scrutiny

What’s Next

Key developments to watch:

  • Which disease areas Lilly selects for the joint R&D programs
  • Whether Insilico’s AI-designed drugs advance through Phase 2 and Phase 3 clinical trials
  • How regulators in the US, EU, and Asia respond to AI-generated drug applications
  • Further consolidation as other pharma giants seek similar exclusive AI partnerships
  • Insilico’s next partnership announcements following its Hong Kong IPO momentum

Conclusion: AI Is Now a Core Drug Discovery Engine

The Insilico-Lilly deal is not an experiment — it is a $2.75 billion commitment to the idea that artificial intelligence can fundamentally change how drugs are found, designed, and brought to patients. For the health tech industry, the message is unambiguous: AI is no longer a feature of drug discovery, it is becoming the foundation of it.

As generative AI platforms mature and more molecules move through clinical trials, the question is no longer whether AI will transform pharma — but which companies will own the most powerful platforms when it does.

Key Takeaways

  • Eli Lilly and Insilico Medicine announced a $2.75 billion AI drug discovery deal on March 29, 2026, with $115 million paid upfront.
  • Lilly received an exclusive global license to develop, manufacture, and commercialize Insilico’s AI-discovered oral therapeutics across multiple disease areas.
  • Insilico’s Pharma.AI platform uses generative AI and large language models to design novel drug molecules end-to-end — from target identification to preclinical candidates.
  • Insilico has developed at least 28 drugs using generative AI, with nearly half already in clinical trials.
  • The deal is Lilly’s latest AI investment, following a partnership with NVIDIA in October 2025 to build the most powerful supercomputer in the pharmaceutical industry.